This comprehensive resource looks at PARP inhibition and DDR as therapeutic targets across multiple tumour types
Assoc. Prof. Caterina Marchio: A lung cancer case
We celebrate our 10-year anniversary at the COR2ED booth during ESMO 2022. In 10 years, 500,000 healthcare professionals have trusted our educational programmes.
COR2ED brings you an update on a selection of late-breaking abstracts presented in the Presidential Symposia at ESMO 2022.
Poster 1: Dufresne A. et al (ESMO 2022)
The role of the nurse in nmCRPC patient management
How will your clinical decisions impact a patient at two key stages in their journey?
Episode 1: Non-Small-Cell Lung Cancer Update: ADAURA trial
An expert perspective on the latest data in precision oncology
An expert panel discussion hosted by eChinaHealth and COR2ED
An overview of gene fusions, gold standard detection methods and treatment implications
Oncologists discuss trial data and treatment approaches from both countries: On-demand webinar
Survey into lung cancer biomarker testing and impact on treatment
Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series
Explore pre-analytical phase challenges and biomarker testing in lung cancer. Moderated by the Oncology Brothers.
Share the survey with patients with lung cancer and their caregivers
Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED
Make decisions for your patient at two key stages in their journey
Looking beyond the obvious mutations in non-small-cell lung cancer
Molecular testing challenges and optimal biomarker testing approaches in lung and prostate cancer
A conference update on lung cancer clinical trial data from ASCO
The latest non-small cell lung cancer data presented at ASCO
Medical experts make recommendations for best practice
Recommendations for best practice
Renowned medical experts share their insights into new data presented at ESMO 2024
Findings from a global survey presented in a poster at ESMO 2024
Expert opinion on the clinical application of artificial intelligence (AI)
Medical experts share their insights on testing and treatment
Two emerging and two established targets
Expert insights on the latest NSCLC data
Best practices and interpretation of results in lung and ovarian cancer
What to know, what to expect, and where to find support
A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC